GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,359. ...

Bullish option flow detected in GSK (GSK) Pharma with 3,057 calls trading, 1.1x expected, and implied vol increasing over 4 points to 29.80%. Feb-25 34 calls and 1/31 weekly 34 calls are the most ...

I believe the company’s currently unprofitable so I question that PEG ratio. GSK, with upcoming RSV vaccine developments and a forward P/E ratio of 10 — the lowest in five years, looks accurate.

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.

Teva Pharmaceutical Industries Ltd. ADR 0.46% $24.53B ...

according to GSK, and while nucleoside/nucleotide analogue (NA) drugs to treat it are available – such as Gilead’s polymerase inhibitor Viread (tenofovir) – there is still no curative treatment.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

The Sekretariat Rakyat Benci Rasuah will not prevent any political party from joining their protest this Saturday. However, the secretariat’s spokesperson, A Tobey Qi-Sean, said there are ...

Last month saw a number of alliances forming in a range of therapeutic spaces but there has been one serial collaborator that stands out – GSK. The British pharma giant seems to have embarked on a ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend ... the scientific consensus that there is no consistent or reliable evidence that ranitidine ...